+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route of Administration, Technology, Dosage Form - Global Forecast to 2030- Product Image
Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route of Administration, Technology, Dosage Form - Global Forecast to 2030- Product Image
Sale

Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route of Administration, Technology, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5715935
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Porcine Vaccines Market grew from USD 1.82 billion in 2024 to USD 1.94 billion in 2025. It is expected to continue growing at a CAGR of 6.81%, reaching USD 2.70 billion by 2030.

Setting the Stage for Porcine Vaccine Market Evolution

The global swine industry faces relentless pressure from a spectrum of viral and bacterial diseases, underscoring the pivotal role of effective vaccination in safeguarding animal health and ensuring food security. In recent years, escalating outbreaks of classical swine fever, porcine reproductive and respiratory syndrome, and emergent influenza strains have propelled vaccine innovation to the forefront of livestock management strategies. Concurrently, intensifying regulatory scrutiny and heightened consumer expectations around animal welfare and antibiotic stewardship have fostered a renewed commitment to proactive immunization programs.

Against this backdrop, the porcine vaccine market is undergoing a profound transformation driven by advances in molecular biology, vaccine delivery technologies, and supply chain optimization. Stakeholders, from commercial farmers to veterinary research institutes, are seeking comprehensive intelligence to inform procurement decisions, streamline immunization schedules, and anticipate the next wave of technological breakthroughs. This executive summary distills key trends, market drivers, and strategic considerations to equip decision-makers with the insights needed to navigate a complex landscape and capitalize on emerging growth opportunities.

Innovations and Policy Shifts Redefining the Vaccine Landscape

The porcine vaccine arena is experiencing a paradigm shift as novel platforms converge with progressive regulatory frameworks to redefine industry standards. Cutting-edge mRNA constructs, once the domain of human therapeutics, are now being optimized for swine, offering rapid development cycles and enhanced immunogenicity. Simultaneously, viral vector platforms leveraging adenovirus and poxvirus backbones are delivering targeted antigen presentation and cross-protective potential, reshaping preventive strategies against endemic pathogens.

Beyond technological advances, policy reforms have accelerated the adoption of precision livestock health initiatives. National mandates in key producing regions now require comprehensive herd immunity metrics, driving integration of digital diagnostics, remote monitoring, and data analytics. This fusion of biotech innovation with real-time surveillance is cultivating a more resilient supply chain, reducing time-to-market for novel formulations, and empowering stakeholders to respond swiftly to emergent threats. As these transformative forces coalesce, the porcine vaccine landscape is poised for sustained expansion underpinned by agility, collaboration, and scientific rigor.

Assessing the Shockwaves of US Tariffs on Porcine Vaccines

In early 2025, the United States instituted a new tariff regime on critical vaccine components, triggering a cascade of repercussions across the global supply chain. Raw material costs have surged, particularly for adjuvants and reagent imports, compelling manufacturers to recalibrate pricing models and negotiate alternative sourcing agreements. These adjustments have had a knock-on effect on formulation expenses, with downstream implications for end users facing tighter operational budgets.

The tariff-induced financial strain has also accelerated efforts to localize production capabilities. Several contract development organizations have announced capacity expansions for active pharmaceutical ingredient synthesis, while strategic alliances between domestic biotech firms and international suppliers seek to mitigate import dependencies. Despite these initiatives, regulatory approvals and scale-up timelines remain challenging, creating a transient period of cost volatility. Decision-makers must therefore account for these headwinds when evaluating procurement strategies, potential inventory buffering, and long-term partnerships that can weather policy shifts and preserve supply chain integrity.

Unpacking Segment Dynamics Driving Market Opportunities

A granular examination of vaccine types reveals a persistent dominance of inactivated platforms, where whole virus and subcellular formulations deliver robust safety profiles for sensitive herds. Yet live attenuated vaccines, be they homologous or heterologous strains, continue to hold strategic value in regions where rapid immunogenic response is essential. The emergence of mRNA-based constructs-spanning self-amplifying and non-amplifying architectures-offers a new frontier for eliciting targeted immunity with streamlined manufacturing processes. Parallel advancements in subunit vaccines, leveraging protein and polysaccharide antigens, and virus-vectored approaches through adenovirus and poxvirus carriers, are diversifying the therapeutic arsenal against multifaceted disease indications.

Among disease segments, control of porcine reproductive and respiratory syndrome remains the primary driver of research and adoption, closely followed by intensified campaigns against classical swine fever. Swine influenza surveillance programs increasingly rely on vaccines with broad strain coverage, while erysipelas prevention underscores the need for combination formulations. End users are making differentiated choices: commercial operations prioritize scalable intramuscular regimens, research institutes foster novel adjuvant exploration, smallholder settings gravitate toward liquid and lyophilized dosage forms for flexible cold-chain management, and veterinary hospitals emphasize injectable administrations to maximize efficacy.

Technological trajectories further illuminate market dynamics. Conventional attenuated live and killed whole systems retain foundational value, even as DNA platforms assert their presence. Recombinant expressions in bacterial, insect cell, and yeast hosts are delivering cost efficiencies, and the rise of RNA and virus-like particle constructs signals a bold shift toward molecular precision. Meanwhile, dosage forms such as emulsions enhance antigen delivery, liquids simplify field application, and lyophilized powders ensure stability in decentralized environments. This mosaic of segment insights highlights areas where targeted investment and tailored development will yield the highest return on innovation.

Regional Trends Shaping Global Porcine Vaccine Adoption

Regional nuances are profoundly shaping the global trajectory of porcine vaccines. In the Americas, robust biotech infrastructure and substantial R&D investment have positioned mRNA and recombinant platforms at the vanguard of disease control efforts. Collaborative alliances between private enterprises and governmental agencies are expediting licensure of next-generation immunogens, reinforcing North America’s role as a trendsetter in scale-up capabilities and best-in-class safety standards.

Across Europe, the Middle East, and Africa, harmonized regulatory frameworks have streamlined cross-border vaccine approvals, enabling manufacturers to leverage centralized reviews for rapid market entry. This regulatory cohesion, coupled with stringent animal welfare mandates, fuels demand for advanced subunit and vectored formulations designed to minimize adverse events. Concurrently, EMEA’s growing emphasis on integrated surveillance systems is driving uptake of intradermal and intranasal delivery methods that facilitate mass immunization with reduced labor costs.

The Asia-Pacific corridor is witnessing an unprecedented acceleration in vaccine rollout, driven by national disease eradication campaigns and expanding commercial swine operations. Governments are incentivizing local production through favorable tax structures and public-private partnerships, fostering a fertile environment for technology transfer and capacity building. Intramuscular and oral administration routes are gaining traction in high-density farming regions, while emergent smallholder communities benefit from portable liquid and lyophilized formats. This combination of policy support and sectoral growth underscores APAC as a critical frontier for portfolio expansion and strategic alliances.

Competitive Landscape and Emerging Industry Players

Leading animal health companies are intensifying their pursuit of breakthrough platforms by forging cross-sector alliances and bolstering internal R&D pipelines. Established multinationals continue to refine their core inactivated and attenuated offerings, integrating next-generation adjuvants to enhance immunogenic durability. Simultaneously, nimble biotech innovators are carving out niches in mRNA and VLP technologies, securing intellectual property positions that promise to redefine efficacy benchmarks.

Strategic partnerships between contract research organizations and vaccine developers are accelerating preclinical workflows, while targeted acquisitions are enabling organizations to vertically integrate critical manufacturing capabilities. Competitive differentiation increasingly hinges on streamlined regulatory pathways and accelerated phase transitions, driving investment into advanced analytics, digital traceability, and real-world evidence platforms. This convergence of scale and agility is reshaping the competitive landscape, with first-mover advantage in novel modalities serving as the fulcrum for market share gains.

Strategic Imperatives for Industry Leadership

Industry leaders must adopt a multifaceted strategy to navigate evolving market dynamics and secure long-term growth. First, prioritizing investment in mRNA and virus-vectored R&D will capitalize on rapid development cycles and address gaps in cross-protective immunity. Second, diversifying raw material sourcing through strategic alliances or localized production hubs can offset tariff-driven cost pressures and stabilize supply chains.

Enhancing portfolio breadth through combination vaccines targeting multiple disease pathways will deliver operational efficiencies for end users and reinforce customer loyalty. Simultaneously, deploying digital diagnostics and data analytics to demonstrate vaccine performance in real-world settings will support regulatory dossiers and strengthen stakeholder trust. Finally, expanding access to smallholder markets with adaptable liquid and lyophilized formulations will unlock new revenue streams while contributing to global herd immunity objectives. By implementing these strategic imperatives, industry players can transform challenges into competitive advantages and lead the next wave of innovation.

Rigorous Methodology Underpinning Our Insights

This analysis is underpinned by a rigorous, multi-tiered research framework combining primary and secondary methodologies. Primary data was collected through structured interviews with veterinary experts, senior executives, and technical specialists spanning leading producers and research institutes. These qualitative insights were complemented by quantitative surveys designed to capture adoption rates, pricing dynamics, and end-user preferences across key regions.

Secondary research involved exhaustive reviews of regulatory filings, scientific literature, patent databases, and proprietary supply chain analytics. Data triangulation techniques ensured alignment between reported figures and on-the-ground sentiment, while scenario analysis illuminated potential market perturbations such as policy shifts and technology breakthroughs. All findings were subjected to peer review by external subject matter experts to validate assumptions and enhance analytical robustness.

Converging Insights and Future Outlook

The porcine vaccine market sits at an inflection point where technological ingenuity, policy evolution, and shifting supply chain paradigms converge to redefine industry benchmarks. As vaccine platforms diversify and regulatory landscapes harmonize, stakeholders have an unprecedented opportunity to leverage data-driven strategies for accelerated product development and market penetration. Segmentation analysis reveals compelling pockets of growth across vaccine types and administration routes, while regional deep dives underscore the critical role of localized innovation and strategic partnerships.

Effective navigation of tariff volatility, supply chain complexities, and emerging disease threats will distinguish market leaders from followers. By synthesizing these insights, decision-makers can refine their strategic roadmaps, prioritize high-impact investments, and deliver sustainable value to livestock producers worldwide. The synthesis of robust methodological rigor and actionable intelligence provides a clear pathway for organizations aiming to maintain resilience and foster growth in a dynamic ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Vaccine Type
    • Inactivated
      • Split Virus
      • Subcellular
      • Whole Virus
    • Live Attenuated
      • Heterologous
      • Homologous
    • MRNA
      • Non Amplifying MRNA
      • Self Amplifying MRNA
    • Subunit
      • Polysaccharide Subunit
      • Protein Subunit
    • Virus Vectored
      • Adenovirus Vector
      • Poxvirus Vector
  • Disease Indication
    • Classical Swine Fever
    • Erysipelas
    • Porcine Reproductive And Respiratory Syndrome
    • Swine Influenza
  • End User
    • Commercial Farm
    • Research Institute
    • Smallholder Farm
    • Veterinary Hospital
  • Route Of Administration
    • Intradermal
    • Intramuscular
    • Intranasal
    • Oral
    • Subcutaneous
  • Technology
    • Conventional
      • Attenuated Live
      • Killed Whole
    • DNA
    • Recombinant
      • Bacteria Expressed
      • Insect Cell Expressed
      • Yeast Expressed
    • RNA
    • VLP
  • Dosage Form
    • Emulsion
    • Liquid
    • Lyophilized
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Ceva Santé Animale S.A.
  • Elanco Animal Health Incorporated
  • HIPRA, S.A.
  • Vetoquinol S.A.
  • Phibro Animal Health Corporation
  • Virbac S.A.
  • Bioveta, a.s.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Porcine Vaccines Market, by Vaccine Type
8.1. Introduction
8.2. Inactivated
8.2.1. Split Virus
8.2.2. Subcellular
8.2.3. Whole Virus
8.3. Live Attenuated
8.3.1. Heterologous
8.3.2. Homologous
8.4. MRNA
8.4.1. Non Amplifying MRNA
8.4.2. Self Amplifying MRNA
8.5. Subunit
8.5.1. Polysaccharide Subunit
8.5.2. Protein Subunit
8.6. Virus Vectored
8.6.1. Adenovirus Vector
8.6.2. Poxvirus Vector
9. Porcine Vaccines Market, by Disease Indication
9.1. Introduction
9.2. Classical Swine Fever
9.3. Erysipelas
9.4. Porcine Reproductive and Respiratory Syndrome
9.5. Swine Influenza
10. Porcine Vaccines Market, by End User
10.1. Introduction
10.2. Commercial Farm
10.3. Research Institute
10.4. Smallholder Farm
10.5. Veterinary Hospital
11. Porcine Vaccines Market, by Route of Administration
11.1. Introduction
11.2. Intradermal
11.3. Intramuscular
11.4. Intranasal
11.5. Oral
11.6. Subcutaneous
12. Porcine Vaccines Market, by Technology
12.1. Introduction
12.2. Conventional
12.2.1. Attenuated Live
12.2.2. Killed Whole
12.3. DNA
12.4. Recombinant
12.4.1. Bacteria Expressed
12.4.2. Insect Cell Expressed
12.4.3. Yeast Expressed
12.5. RNA
12.6. VLP
13. Porcine Vaccines Market, by Dosage Form
13.1. Introduction
13.2. Emulsion
13.3. Liquid
13.4. Lyophilized
14. Americas Porcine Vaccines Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Porcine Vaccines Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Porcine Vaccines Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Zoetis Inc.
17.3.2. Boehringer Ingelheim International GmbH
17.3.3. Merck & Co., Inc.
17.3.4. Ceva Santé Animale S.A.
17.3.5. Elanco Animal Health Incorporated
17.3.6. HIPRA, S.A.
17.3.7. Vetoquinol S.A.
17.3.8. Phibro Animal Health Corporation
17.3.9. Virbac S.A.
17.3.10. Bioveta, a.s.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PORCINE VACCINES MARKET MULTI-CURRENCY
FIGURE 2. PORCINE VACCINES MARKET MULTI-LANGUAGE
FIGURE 3. PORCINE VACCINES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PORCINE VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 89. CANADA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 90. CANADA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 91. CANADA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 92. CANADA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 93. CANADA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 94. CANADA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 95. CANADA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 96. CANADA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. CANADA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. CANADA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 99. CANADA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 100. CANADA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 101. CANADA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 102. MEXICO PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 104. MEXICO PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 105. MEXICO PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 106. MEXICO PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 107. MEXICO PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 108. MEXICO PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 109. MEXICO PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 111. MEXICO PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. MEXICO PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 113. MEXICO PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 114. MEXICO PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 168. GERMANY PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 169. GERMANY PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 170. GERMANY PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 171. GERMANY PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 172. GERMANY PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 173. GERMANY PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 174. GERMANY PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 175. GERMANY PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 176. GERMANY PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. GERMANY PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 179. GERMANY PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 180. GERMANY PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 181. FRANCE PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 182. FRANCE PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 183. FRANCE PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 184. FRANCE PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 185. FRANCE PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 186. FRANCE PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 187. FRANCE PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 188. FRANCE PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. FRANCE PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. FRANCE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 191. FRANCE PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 192. FRANCE PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 193. FRANCE PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 207. ITALY PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 208. ITALY PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 209. ITALY PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 210. ITALY PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 211. ITALY PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 212. ITALY PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 213. ITALY PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 214. ITALY PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ITALY PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. ITALY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 217. ITALY PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 218. ITALY PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 219. ITALY PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 220. SPAIN PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 221. SPAIN PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 222. SPAIN PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 223. SPAIN PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 224. SPAIN PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 225. SPAIN PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 226. SPAIN PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 227. SPAIN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. SPAIN PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 229. SPAIN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. SPAIN PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 231. SPAIN PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 232. SPAIN PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 272. DENMARK PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 273. DENMARK PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 274. DENMARK PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 275. DENMARK PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 276. DENMARK PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 277. DENMARK PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 278. DENMARK PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 279. DENMARK PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. DENMARK PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. DENMARK PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 282. DENMARK PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 283. DENMARK PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 284. DENMARK PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 296. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 298. QATAR PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 299. QATAR PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 300. QATAR PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 301. QATAR PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 302. QATAR PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 303. QATAR PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 304. QATAR PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 305. QATAR PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 306. QATAR PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. QATAR PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 308. QATAR PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 309. QATAR PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 310. QATAR PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 311. FINLAND PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 312. FINLAND PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 313. FINLAND PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 314. FINLAND PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 315. FINLAND PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 316. FINLAND PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 317. FINLAND PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 318. FINLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 319. FINLAND PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 320. FINLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 321. FINLAND PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 322. FINLAND PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 323. FINLAND PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 324. SWEDEN PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 325. SWEDEN PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 326. SWEDEN PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 327. SWEDEN PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 328. SWEDEN PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 329. SWEDEN PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 330. SWEDEN PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 331. SWEDEN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 332. SWEDEN PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. SWEDEN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 334. SWEDEN PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 335. SWEDEN PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 336. SWEDEN PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 337. NIGERIA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 338. NIGERIA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 339. NIGERIA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 340. NIGERIA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 341. NIGERIA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2030 (USD MILLION)
TABLE 342. NIGERIA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2030 (USD MILLION)
TABLE 343. NIGERIA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 344. NIGERIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 345. NIGERIA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 346. NIGERIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 347. NIGERIA PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2030 (USD MILLION)
TABLE 348. NIGERIA PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 349. NIGERIA PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 350. EGYPT PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 351. EGYPT PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 352. EGYPT PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 353. EGYPT PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2030 (USD MILLION)
TABLE 354. EGYPT PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 20

Companies Mentioned

The companies profiled in this Porcine Vaccines market report include:
  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Ceva Santé Animale S.A.
  • Elanco Animal Health Incorporated
  • HIPRA, S.A.
  • Vetoquinol S.A.
  • Phibro Animal Health Corporation
  • Virbac S.A.
  • Bioveta, a.s.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.94 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.7 Billion
Compound Annual Growth Rate6.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Porcine Vaccine Market Report 2025 - Product Image

Porcine Vaccine Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Global Porcine Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Porcine Vaccine - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 120 Pages
  • Global
From
Porcine Vaccines - Global Strategic Business Report - Product Image

Porcine Vaccines - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Porcine Vaccine Market 2024-2028 - Product Image

Porcine Vaccine Market 2024-2028

  • Report
  • 157 Pages
  • Global
From
Swine Vaccines Market by Vaccine Type, Animal Age, Route Of Administration, Packaging Type, End User, Disease Type, Distribution Channel - Global Forecast to 2030 - Product Image

Swine Vaccines Market by Vaccine Type, Animal Age, Route Of Administration, Packaging Type, End User, Disease Type, Distribution Channel - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From

About the Swine Vaccine Market

The Swine Vaccine market is a segment of the Animal Pharmaceuticals industry that focuses on the development and production of vaccines for swine. Vaccines are used to protect swine from a variety of diseases, including Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus (PCV), and Classical Swine Fever (CSF). Vaccines are typically administered to swine through injection or oral administration. The Swine Vaccine market is highly competitive, with a number of companies offering a variety of products. Companies in the market include Merck Animal Health, Zoetis, Elanco, Boehringer Ingelheim, and Ceva Sante Animale. These companies offer a range of products, including vaccines for PRRS, PCV, and CSF, as well as other vaccines for swine. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.